Fármaco que reduce el deseo de beber alcohol
En este Short veremos cómo un fármaco para otra función podría ser una gran ayuda para consumir menos alcohol. …
Uncategorized
SYMBYX announces promising Sydney Adventist Hospital clinical trial results for Parkinson’s using the SYMBYX Neuro – a new light therapy wellness helmet
SYMBYX today announced the results of a Sydney Adventist Hospital (commonly known as the San) triple-blinded, randomised controlled trial investigating the effects of a new red/infrared light therapy helmet on patients living with Parkinson’s Disease.
Zomedica Appoints New Chief Financial Officer
Zomedica Corp., a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Peter L. Donato as its Chief Financial Officer, effective March 16, 2023.
Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program
Biophytis SA annouces that it will change the ratio of its American Depositary Shares to Biophytis ordinary shares from one ADS representing 10 Shares, to one ADS representing 100 Shares.
Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program Read More »
Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACR
Medivir AB announces that data from the company’s leading program fostroxacitabine bralpamide and its potential effect on hepatocellular carcinoma, will be presented at the American Association for Cancer Research Annual Meeting, on April 14-19, in Orlando, USA.
IRLAB to Hold Four Presentations at Scientific Congress AD/PD(TM) 2023
IRLAB Therapeutics AB announced that it will present new data in an oral presentation and hold three poster presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD ™ 2023, held on March 28- April 1, 2023, in Gothenburg, Sweden.
IRLAB to Hold Four Presentations at Scientific Congress AD/PD(TM) 2023 Read More »
Kelyniam Global Announces Record Sales of $3 million in 2022 Financial Statements
Kelyniam Global, a maker of custom cranial implants, announced results for its year ended December 31, 2022.
Kelyniam Global Announces Record Sales of $3 million in 2022 Financial Statements Read More »
Avivagen Inc. Announces Results for the First Quarter Ending January 31, 2023
Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the first quarter of 2023.
Avivagen Inc. Announces Results for the First Quarter Ending January 31, 2023 Read More »
Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67% Five-Year Overall Survival Rate Compared to 8.2% in Institutional Database
CANbridge Pharmaceuticals, Inc. announced that long-term follow up data from the Phase 1/2 study of CAN008 plus temozolomide/radiotherapy in newly diagnosed glioblastoma multiforme showed a long-term survival rate of 67% at five years, three years after the trial ended.
CMS lays out plans for negotiating drug prices
The guidance fills in details for one of the central pharmaceutical provisions of the Inflation Reduction Act, signaling how the agency will use its new authority.